Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Moshe Levin

Chaim Salomon

Yitschak Elstein

Teva Pharmaceutical Industries Limited

Pharma Manufacturing provides information and resources related to the pharmaceutical manufacturing sector, including industry news, articles, and events.

Pharma Manufacturing

CheckMark Labrecruitment specializes in recruitment for laboratory vacancies in the chemistry and life sciences sectors. It offers services to both candidates seeking jobs and companies looking for laboratory personnel. Self-described as having a large network of clients in chemie, biotech, food, and pharma.

Metric
Company Name	Teva Pharmaceutical Industries Limited	Pharma Manufacturing	CheckMark Labrecruitment
Symbol	TEVA
MSH ID	COM:TEVAPHARM	COM:PHARMAMANUFACTURING	NL:CHECKMARK
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Commercial & Professional Services	Commercial & Professional Services
Industry	Drug Manufacturers - Specialty & Generic	Pharmaceuticals	Recruitment & Staffing
Country	IL	US	NL
Stage	Equity
Employee Count	35.00K
Website	tevapharm.com	pharmamanufacturing.com	checkmark.nl
LinkedIn			checkmark-labrecruitment
Founders

Metric
Market Cap	19.23B
Enterprise Value
Monthly Web Traffic	266.70K	6.54K
Web Traffic Growth	0.27	-0.82
Valuation
Raised Capital	100M

Metric
Revenue	15.85B
Revenue (LTM)
Revenue (NTM)
Gross Profit	7.64B
EBITDA	433M
Operating Income	433M
Net Income	-559M
EPS	-0.50
Diluted EPS	-0.49
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.50
Operating Profit Margin	0.16
EBITDA Margin	0.03
Net Profit Margin	-0.03
Return on Equity	-0.07
Return on Assets	-0.01
Return on Capital Employed	0.09

COM:TEVAPHARM

Teva Pharmaceutical Industries Ltd.

Last Close

17.08

22/11 21:00

Market Cap

19.23B

Beta: -

Volume Today

6.01M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-26.33
P/B Ratio	1.71
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.31
EV Multiple	1.05

Metric
Days Sales Outstanding	78.50
Days Payables Outstanding
Days Inventory Outstanding	178.96
Operating Cycle	258.53
Cash Conversion Cycle	153.57
Asset Turnover	0.39

Metric
Operating Cash Flow	1.37B
Free Cash Flow	842M
Cash Flow to Debt	0.10
Operating Cash Flow/Sales	0.11
Free Cash Flow Yield	0.06

Metric
Cash & Equivalents	3.23B
Accounts Receivable	12M
Inventory	4.02B
Goodwill	17.18B
Debt to Capitalization	0.75
Debt to Assets	0.46
Current Ratio	1.02
Quick Ratio	0.61

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue	0.06
SG&A to Revenue	0.07